Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 6, 2015

View Archived Issues

SKY92 gene expression signature combined with ISS in MM survival prognosis

Transient expression of ZSCAN4 corrects trisomy in cells from people with Down syndrome

Homozygous mutation in PPP1R15B leads to beta-cell dysfunction and diabetes

New financing round at Pharmalink to fund development of phase III program for Nefecon

Nivolumab shows enhanced overall survival in mRCC patients

Genzyme opts into Alnylam Pharmaceuticals' ALN-AT3 hemophilia program

BioCancell advances combination of BC-819 and BCG for bladder cancer

Cellectar Biosciences awarded grant to advance phospholipid drug conjugate platform

REV-002 reduces joint pain in phase IIa trial in acute gout arthritis

DeuteRx completes financing to fund clinical trials of DRX-065 for adrenoleukodystrophy

Arvinas enters license agreement with Genentech to develop therapeutics based on PROTAC technology

Celdara and Pulmatrix receive NIH grant to develop inhaled biologic for IPF

Photocure initiates phase III study of Cysview with blue light cystoscopy in surveillance setting

New approaches for the treatment of diabetes: ECM capsules and bioactive nanocoatings

Novel mitochondrial RNA mutation linked to breast cancer

IAPs show promise for the treatment of M. tuberculosis and M. avium infections

Anthera begins phase III SOLUTION study of oral Sollpura

Encore Vision starts phase I/II trial of EV-06 in presbyopia

Algiax discloses GABA(A) receptor modulators

Bristol-Myers Squibb introduces NS5B inhibitors

Yissum reports mushroom ostreolyisin compositions

Nivalis Therapeutics divulges CFTR modulators

AstraZeneca introduces ENaC modulators

Innate Pharma initiates phase I/II trial of IPH-2201 in combination with ibrutinib for CLL

FDA approves Aristada for schizophrenia

Cardinal Health completes acquisition of J&J's Cordis business

Cobimetinib increases overall survival in patients with melanoma treated with vemurafenib

Gilead's new treatment combination of Letairis and tadalafil gains FDA approval for PAH

Cell Therapy plans European CMA submission for Heartcel

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...